Measurement and cellular sources of the soluble interleukin-2 receptor in primary central nervous system lymphoma

被引：8

作者：

Kitai, Ryuhei ^{[1
]}

Sasaki, Hirohito ^{[1
]}

Matsuda, Ken ^{[1
]}

Tsunetoshi, Kenzo ^{[1
]}

Yamauchi, Takahiro ^{[1
]}

Neishi, Hiroyuki ^{[1
]}

Matsumura, Kazuki ^{[1
]}

Tsunoda, Akira ^{[1
]}

Takeuchi, Hiroaki ^{[1
]}

Sato, Kazufumi ^{[1
]}

Kikuta, Ken-ichiro ^{[1
]}

机构：

[1] Univ Fukui, Fac Med Sci, Dept Neurosurg, Fukui 910, Japan

来源：

BRAIN TUMOR PATHOLOGY | 2013年 / 30卷 / 01期

关键词：

Primary CNS lymphoma; CD25; sIL-2R;

D O I：

10.1007/s10014-012-0093-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aims of this study were to determine the diagnostic utility of the serum levels of the soluble interleukin 2 receptor (sIL-2R) as a tumor marker of primary central nervous system lymphoma (PCNSL) and to investigate the cellular source of sIL-2R using immunohistochemical staining. The serum sIL-2R levels of 37 samples from suspected PCNSL patients were measured. There were 13 patients with PCNSL and 24 patients with other diseases such as glioma, metastatic tumor, inflammation, or cerebrovascular disease. The serum sIL-2R levels of the PCNSL cases and other brain diseases were 629.5 +/- A 586.0 U/ml (mean +/- A SD; range 189-2220 U/ml) and 408.5 +/- A 250.7 U/ml (160-837 U/ml), respectively. The serum sIL-2R levels of the two groups overlapped, and hence the difference between them was not significant. sIL-2R is the alpha subunit of IL-2R. It is also known as CD25, and is cleaved from its position in the cell membrane and released into the blood. CD25 expression was immunohistochemically detected in 7 of 11 PCNSL samples. Confocal laser microscopy revealed that CD25 signals were present in atypical cells and mononuclear cells. We concluded that both lymphoma cells and infiltrating T cells express CD25, which is one of the cellular sources of sIL-2R.

引用

页码：34 / 39

页数：6

共 12 条

[1]

Alenius GM, 2009, CLIN EXP RHEUMATOL, V27, P120

[2] Serum soluble interleukin 2 receptor in human cancer of adults and children: a review [J].

Bien, E. ;

Balcerska, A. .

BIOMARKERS, 2008, 13 (01) :1-26

[3] Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy [J].

Ennishi, D. ;

Yokoyama, M. ;

Terui, Y. ;

Asai, H. ;

Sakajiri, S. ;

Mishima, Y. ;

Takahashi, S. ;

Komatsu, H. ;

Ikeda, K. ;

Takeuchi, K. ;

Tanimoto, M. ;

Hatake, K. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :526-533

[4]

Fujimaki T, 2010, NIHON RINSHO, V68, P289

[5]

JACK CR, 1985, AM J NEURORADIOL, V6, P899

[6] Primary central nervous system lymphoma secretes monocyte chemoattractant protein 1 [J].

Kitai, Ryuhei ;

Ishisaka, Kazuyo ;

Sato, Kazufumi ;

Sakuma, Takahiro ;

Yamauchi, Takahiro ;

Imamura, Yoshiaki ;

Matsumoto, Hideki ;

Kubota, Toshihiko .

MEDICAL MOLECULAR MORPHOLOGY, 2007, 40 (01) :18-22

[7]

Louis DN, 2007, MALIGNANT LYMPHOMAS, P188

[8] SELECTIVE INVITRO GROWTH OF T-LYMPHOCYTES FROM NORMAL HUMAN BONE MARROWS [J].

MORGAN, DA ;

RUSCETTI, FW ;

GALLO, R .

SCIENCE, 1976, 193 (4257) :1007-1008

[9] Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus [J].

Pereira, Flavia Ozorio ;

Frode, Tania Silvia ;

Medeiros, Yara Santos .

MEDIATORS OF INFLAMMATION, 2006, 2006

[10] THE SOLUBLE INTERLEUKIN-2 RECEPTOR - BIOLOGY, FUNCTION, AND CLINICAL-APPLICATION [J].

RUBIN, LA ;

NELSON, DL .

ANNALS OF INTERNAL MEDICINE, 1990, 113 (08) :619-627

← 1 2 →